Retrophin - רווח למניה ב-12 החודשים האחרונים TVTX

Travere Therapeutics (TVTX) shows growth in rolling trailing twelve-month net income per share driven by premium pricing for its innovative therapy. The value -59.00 indicates the current level of this metric. Business stability relies on an ethical corporate culture and the retention of key talent, although global logistical disruptions and sanctions limit access to certain foreign markets for drug distribution.
פילוחי מדדים פיננסיים ומדדי שוק עבור Retrophin (TVTX)

The revenue stability of Travere Therapeutics (TVTX) from rare kidney disease therapies is constrained by the dependence of profits on the scaling of new products. By analyzing the current EPS TTM YoY growth rate on the GURU.Markets platform, an investor assesses the rolling annual net profit trend, where daily data updates allow for the timely detection of deviations from the market consensus and the avoidance of overpaying for inflated expectations.